BioRestorative Therapies, Inc. SEC filings BRTX

BioRestorative Therapies, Inc. has 754 filings in SEC EDGAR's recent list, going back to Nov 16, 2010. Its latest annual report, Form 10-K, was filed on Mar 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 14, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (officer or director change). The company's fiscal year ends on December 31.

Form Description Filed Period
10-K Annual report Mar 26, 2026 Dec 31, 2025
10-K Annual report Mar 28, 2025 Dec 31, 2024
10-K/A Amended annual report Nov 6, 2024 Dec 31, 2023
10-K/A Amended annual report Jun 11, 2024 Dec 31, 2023
10-K Annual report Apr 1, 2024 Dec 31, 2023
10-K Annual report Mar 27, 2023 Dec 31, 2022
10-K Annual report Mar 30, 2022 Dec 31, 2021
10-K Annual report Apr 30, 2021 Dec 31, 2020
10-K Annual report Mar 18, 2021 Dec 31, 2019
10-K Annual report Mar 29, 2019 Dec 31, 2018
10-K Annual report Apr 2, 2018 Dec 31, 2017
10-K Annual report Mar 22, 2017 Dec 31, 2016
10-K Annual report Mar 30, 2016 Dec 31, 2015
10-K Annual report Mar 31, 2015 Dec 31, 2014
10-K Annual report Apr 11, 2014 Dec 31, 2013
10-K Annual report Apr 2, 2013 Dec 31, 2012
10-K Annual report Apr 16, 2012 Dec 31, 2011

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Services-Misc Health & Allied Services, NEC (SIC 8090)
Listed as
BRTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Melville, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1505497
Former names
Stem Cell Assurance, Inc. (until Aug 16, 2011)

Other Services-Misc Health & Allied Services, NEC companies

All 15 Services-Misc Health & Allied Services, NEC companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.